1240 related articles for article (PubMed ID: 16157541)
1. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of [99mTc/EDDA/tricine/HYNIC0, 1-Nal3, Thr8]-octreotide as a new analogue in the detection of somatostatin-receptor-positive tumors.
Gandomkar M; Najafi R; Shafiei M; Mazidi M; Ebrahimi SE
Nucl Med Biol; 2007 Aug; 34(6):651-7. PubMed ID: 17707805
[TBL] [Abstract][Full Text] [Related]
3. Preparation and biological evaluation of [(99m)Tc/EDDA/Tricine/HYNIC(0), BzThi(3)]-octreotide for somatostatin receptor-positive tumor imaging.
Erfani M; Shafiei M; Mazidi M; Goudarzi M
Cancer Biother Radiopharm; 2013 Apr; 28(3):240-7. PubMed ID: 23464855
[TBL] [Abstract][Full Text] [Related]
4. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
[TBL] [Abstract][Full Text] [Related]
5. [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.
Maina T; Nock BA; Cordopatis P; Bernard BF; Breeman WA; van Gameren A; van den Berg R; Reubi JC; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):831-40. PubMed ID: 16568203
[TBL] [Abstract][Full Text] [Related]
6. 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.
Decristoforo C; Melendez-Alafort L; Sosabowski JK; Mather SJ
J Nucl Med; 2000 Jun; 41(6):1114-9. PubMed ID: 10855644
[TBL] [Abstract][Full Text] [Related]
7. Tetraamine-modified octreotide and octreotate: labeling with 99mTc and preclinical comparison in AR4-2J cells and AR4-2J tumor-bearing mice.
Nikolopoulou A; Maina T; Sotiriou P; Cordopatis P; Nock BA
J Pept Sci; 2006 Feb; 12(2):124-31. PubMed ID: 16059963
[TBL] [Abstract][Full Text] [Related]
8. (99m)Tc-labeled dimeric octreotide peptide: a radiotracer with high tumor uptake for single-photon emission computed tomography imaging of somatostatin receptor subtype 2-positive tumors.
Dong C; Zhao H; Yang S; Shi J; Huang J; Cui L; Zhong L; Jin X; Li F; Liu Z; Jia B; Wang F
Mol Pharm; 2013 Aug; 10(8):2925-33. PubMed ID: 23768172
[TBL] [Abstract][Full Text] [Related]
9. Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Forssell-Aronsson E
Cancer Biother Radiopharm; 2005 Apr; 20(2):231-6. PubMed ID: 15869461
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
[TBL] [Abstract][Full Text] [Related]
11. Tecnetium-99m as alternative to produce somatostatin-labeled derivatives: comparative biodistribution evaluation with 111In-DTPA-octreotide.
Melo IB; Ueda LT; Araujo EB; Muramoto E; Barboz MF; Mengatti J; Buchpiguel CA; Silva CP
Cell Mol Biol (Noisy-le-grand); 2010 May; 56(2):31-6. PubMed ID: 20525456
[TBL] [Abstract][Full Text] [Related]
12. Initial direct comparison of 99mTc-TOC and 99mTc-TATE in identifying sites of disease in patients with proven GEP NETs.
Cwikla JB; Mikolajczak R; Pawlak D; Buscombe JR; Nasierowska-Guttmejer A; Bator A; Maecke HR; Walecki J
J Nucl Med; 2008 Jul; 49(7):1060-5. PubMed ID: 18552141
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, radiolabeling, and preclinical evaluation of a new octreotide analog for somatostatin receptor-positive tumor scintigraphy.
De K; Bhowmik A; Behera A; Banerjee I; Ghosh MK; Misra M
J Pept Sci; 2012 Dec; 18(12):720-30. PubMed ID: 23109400
[TBL] [Abstract][Full Text] [Related]
14. Analysis of accumulation of 99mTc-octreotide and 99mTc-EDDA/HYNIC-Tyr3-octreotide in the rat kidneys.
Kopecky M; Semecky V; Trejtnar F; Laznicek M; Laznickova A; Nachtigal P; Decristoforo C; Mather SJ; Mäcke HR
Nucl Med Biol; 2004 Feb; 31(2):231-9. PubMed ID: 15013489
[TBL] [Abstract][Full Text] [Related]
15. An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.
Gabriel M; Decristoforo C; Donnemiller E; Ulmer H; Watfah Rychlinski C; Mather SJ; Moncayo R
J Nucl Med; 2003 May; 44(5):708-16. PubMed ID: 12732671
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.
Ginj M; Chen J; Walter MA; Eltschinger V; Reubi JC; Maecke HR
Clin Cancer Res; 2005 Feb; 11(3):1136-45. PubMed ID: 15709181
[TBL] [Abstract][Full Text] [Related]
17. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, characterization, conformational analysis of a cyclic conjugated octreotate peptide and biological evaluation of (99m)Tc-HYNIC-His(3)-Octreotate as novel tracer for the imaging of somatostatin receptor-positive tumors.
Behera A; Banerjee I; De K; Munda RN; Chattopadhayay S; Samanta A; Sarkar B; Ganguly S; Misra M
Amino Acids; 2013 Mar; 44(3):933-46. PubMed ID: 23090293
[TBL] [Abstract][Full Text] [Related]
19. In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111.
Trejtnar F; Novy Z; Petrik M; Laznickova A; Melicharova L; Vankova M; Laznicek M
Ann Nucl Med; 2008 Dec; 22(10):859-67. PubMed ID: 19142704
[TBL] [Abstract][Full Text] [Related]
20. Tumour uptake of the radiolabelled somatostatin analogue [DOTA0, TYR3]octreotide is dependent on the peptide amount.
de Jong M; Breeman WA; Bernard BF; van Gameren A; de Bruin E; Bakker WH; van der Pluijm ME; Visser TJ; Mäcke HR; Krenning EP
Eur J Nucl Med; 1999 Jul; 26(7):693-8. PubMed ID: 10398816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
